Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 13/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25938179 | 0.82 | MAP4K1 (0.35) | MAP4K1PARP1KDM4EMAPTUSP2 | |
| SCHEMBL21703026 | 0.81 | MAP4K1 (0.50) | MAP4K1PARP1KDM4EMAPTHSD17B10 | |
| SCHEMBL21702894 | 0.79 | MAP4K1 (0.36) | MAP4K1PARP1ELANE | |
| SCHEMBL21703151 | 0.78 | MAP4K1 (0.41) | MAP4K1CHEK1ELANE | |
| SCHEMBL25938865 | 0.75 | MAP4K1 (0.58) | MAP4K1 | |
| SCHEMBL21703328 | 0.73 | MAP4K1 (0.55) | MAP4K1CHEK1ELANE | |
| SCHEMBL23452764 | 0.72 | MAP4K1 (0.42) | MAP4K1PARP1KDM4EHPGDCHEK1 | |
| SCHEMBL21685422 | 0.72 | MAP4K1 (0.53) | MAP4K1PARP1CHEK1ELANE | |
| SCHEMBL21685880 | 0.72 | MAP4K1 (0.42) | MAP4K1MAPTCHEK1ELANE | |
| SCHEMBL21703101 | 0.71 | MAP4K1 (0.41) | MAP4K1PARP1KDM4EELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020033784-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | MAP4K1 2520/4885PARP1 2945/4885KDM4E 2034/4885 |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | MAP4K1 2520/4885PARP1 2945/4885KDM4E 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.